Bio-Rad Introduces the GelDoc Go Imaging System, a Personal Benchtop System for Imaging of Gels and Colorimetric Blots

Date: 
05/06/2020
GelDoc Go Imaging System
GelDoc Go Imaging System offers documentation of nucleic acid and protein gels, Stain-Free blots and gels, and colorimetric blots.

HERCULES, Calif. – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its GelDoc Go Imaging System, a personal benchtop system for the documentation of nucleic acid and protein gels, Stain-Free blots and gels, and colorimetric blots.

The GelDoc Go Imaging System is the latest imaging system from the company’s GelDoc product line, offering sensitivity, performance, and reliability in a compact system. Its easy-to-use and intuitive software provides researchers a way generate images with just a few screen touches, saving time and providing results quickly.

"The GelDoc Go System is an easy-to-use and compact solution for gel documentation," said Paul Liu, Bio-Rad Product Manager, Western Blotting. "Using the system, researchers can generate publication-ready images quickly and reliably, and the system is backed by Bio-Rad’s service and support."

Key Benefits of the GelDoc Go Imaging System

  • Capture high resolution and publication-quality images at your bench
  • Easy-to-use and intuitive software allows users to generate images with just a few screen touches, saving time and providing results quickly
  • Offers intuitive software and user interface
  • Flexible imaging options include: full nucleic acid gels, protein gels, Stain-Free gels, or colorimetric blots
  • Pinch and zoom functionality help capture and print key areas of interest
  • Compact footprint conserves bench space
  • Users can image up to four mini-sized gels simultaneously with the system's large imaging area
  • IQ/OQ tools and software offer easy management of user accounts and permissions

Learn more about the GelDoc Go Imaging System.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,100 employees worldwide. Bio-Rad had revenues exceeding $2.3 billion in 2019. For more information, please visit bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Press Contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications
510-724-7000
tina_cuccia@bio-rad.com